Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Yosra M. Aljawai, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Portia Smallbone, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2024) 144 (Supplement 1): 7441.

https://doi.org/10.1182/blood-2024-210279

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Natalie Rafaeli, Rima M. Saliba, Jayastu Senapati, Naval Daver, Portia Smallbone, Partow Kebriaei, David Marin, Uday Popat, Tapan M. Kadia, Farhad Ravandi, George Chen, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2024-201718

Published: 2024

Journal Articles

Age and CAR T-Cell Therapy: Assessing Outcomes across Different Age Groups

Jia Yi Tan, Yong Hao Yeo, Qi Xuan Ang, George Chen, Kok Hoe Chan

Blood (2024) 144 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2024-210139

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Jeremy Ramdial, Lorlyn Clemente, Pinaki Banerjee, Bouthaina S. Dabaja, Gheath Al-Atrash, Amin M. Alousi, Betul Oran, Uday Popat, Jin S. Im, Samer A. Srour, George Chen, Partow Kebriaei, Chitra Hosing, David Marin, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2024-211389

Published: 2024

Journal Articles

Cytokines associated with organ manifestations in chronic graft-versus-host disease

Stephanie J. Lee, Ningxin Ma, Timothy Randolph, Carrie L. Kitko, Corey S. Cutler, Najla El Jurdi, George Chen, Betty K. Hamilton, Joseph A. Pidala, Paul A Carpenter, Sally Arai, Lynn Onstad, Sophie Paczesny, Tomoko Sekiguchi, Motoko Koyama, Geoffrey R. Hill

Blood (2024) 144 (Supplement 1): 4902.

https://doi.org/10.1182/blood-2024-203743

Published: 2024

Journal Articles

HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Portia Smallbone, Kai Cao, Rima M. Saliba, Michele Alvarez, Warren B Fingrut, Yosra Aljawai, Amanda L. Olson, Amin M. Alousi, George Chen, Jeremy Ramdial, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 4937.

https://doi.org/10.1182/blood-2024-200238

Published: 2024

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Cyclosporine May Inhibit the Effect of Extra-Physiologic Oxygen Shock/Stress on Peripheral Blood Stem Cells

Amro Elshoury, MBBChir, Hans Minderman, PhD, Alexis Conway, PhD, Paul K. Wallace, MS, PhD, Charlie Mantel, Joseph Dennis Tario, PhD, Yeong Choi, Kieran O'Loughin, MS, Carlos Cedeno, PhD, Jenna Nichols, Kahteong Soh, MS, Philip L. McCarthy, MD, George Chen, MD

Blood (2018) 132 (Supplement 1): 3346.

https://doi.org/10.1182/blood-2018-99-119329

Published: 2018

Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2018-99-111914

Published: 2018

Journal Articles

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Blood (2017) 130 (Supplement 1): 72.

https://doi.org/10.1182/blood.V130.Suppl_1.72.72

Published: 2017

Journal Articles

Analysis of Anti-CMV T-Cell Immunity and CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation

George Chen, MD, Yali Zhang, MS, Joseph Dennis Tario, PhD, Amanda Herko Przespolewski, MD, Dalin Pan, Patrick Mellors, MD, Christine Ho, MD, Sophia R. Balderman, MD, Maureen Ross, MD PhD, Liselotte Brix, PhD, Paul K. Wallace, MS,PhD, Philip L. McCarthy, MD, Theresa Hahn, PhD

Blood (2017) 130 (Supplement 1): 4496.

https://doi.org/10.1182/blood.V130.Suppl_1.4496.4496

Published: 2017

Journal Articles

Prevalence and Risk-Factors for Financial Burden in Patients with Chronic Graft-Versus-Host Disease: A Cross-Sectional Survey from the Chronic Gvhd Consortium

Nandita Khera, MD, Madan Jagasia, MD MBBS, MS, Raewyn Broady, MBChB, FRACP, Lynn E. Onstad, ScM, Betty K. Hamilton, MD, George Chen, MD, Amin M. Alousi, Stefanie Sarantopoulos, MD PhD, Joseph Pidala, MD PhD, Mary E. Flowers, MD, Philip L. McCarthy, MD, Mukta Arora, MD, Corey Cutler, MD MPH, FRCPC, William A. Wood, MD MPH, Alex Ganetsky, PharmD, Gregory A. Abel, MD, Navneet S. Majhail, MD MS, Stephanie J Lee, MD MPH

Blood (2017) 130 (Supplement 1): 530.

https://doi.org/10.1182/blood.V130.Suppl_1.530.530

Published: 2017

Journal Articles

Housing Mice At Sub-Thermoneutral Temperatures Influences Severity Of Gvhd In Mouse Models

Kathleen M Kokolus, MS, Nicholas D Leigh, BS, George Chen, MD, Philip L. McCarthy, Jr., MD, Xuefang Cao, PhD, Elizabeth A Repasky, PhD

Blood (2013) 122 (21): 5422.

https://doi.org/10.1182/blood.V122.21.5422.5422

Published: 2013

Journal Articles

ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,

George F. Widhopf, II, PhD, Bing Cui, Ph.D., Esther Avery, B.S., George Chen, B.S., Masato Obara, MD, PhD, Karen Messer, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3905.

https://doi.org/10.1182/blood.V118.21.3905.3905

Published: 2011

NARROW

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Age and CAR T-Cell Therapy: Assessing Outcomes across Different Age Groups

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Cytokines associated with organ manifestations in chronic graft-versus-host disease

HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Cyclosporine May Inhibit the Effect of Extra-Physiologic Oxygen Shock/Stress on Peripheral Blood Stem Cells

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Analysis of Anti-CMV T-Cell Immunity and CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation

Prevalence and Risk-Factors for Financial Burden in Patients with Chronic Graft-Versus-Host Disease: A Cross-Sectional Survey from the Chronic Gvhd Consortium

Housing Mice At Sub-Thermoneutral Temperatures Influences Severity Of Gvhd In Mouse Models

ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only